Role of triptolide as an adjunct chemotherapy for ovarian cancer

Chemotherapy

Volumn 54, Issue 1, 2007, Pages 67-76

  Westfall, Suzanne D ^a   Nilsson, Eric E ^a   Skinner, Michael K ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Carboplatin; LY294002; Ovarian cancer; Phosphatidylinositol 3 kinase inhibitor; Triptolide

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CARBOPLATIN; TRIPTOLIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER REGRESSION; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MONITORING; MOUSE; NONHUMAN; NUDE MOUSE; OBSERVATIONAL STUDY; OVARY CANCER; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARBOPLATIN; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; CHROMONES; DITERPENES; DRUG SYNERGISM; ENZYME INHIBITORS; EPOXY COMPOUNDS; FEMALE; HUMANS; MICE; MICE, NUDE; MORPHOLINES; OVARIAN NEOPLASMS; PHENANTHRENES; REMISSION INDUCTION; TRIPTERYGIUM; TUMOR BURDEN;

EID: 37349127480     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112419     Document Type: Article

References (38)

1. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC: The biology of ovarian cancer. Semin Oncol 1998;25:281-304.
2. Katabuchi H, Okamura H: Cell biology of human ovarian surface epithelial cells and ovarian carcinogenesis. Med Electron Microsc 2003;36:74-86.
3. Shepherd JE: Current strategies for prevention, detection, and treatment of ovarian cancer. J Am Pharm Assoc (Wash) 2000;40:392-401.
4. Herrin VE, Thigpen JT: Chemotherapy for ovarian cancer: current concepts. Semin Surg Oncol 1999;17:181-188.
5. Marsden DE, Friedlander M, Hacker NF: Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol 2000;19:11-19.
6. McGuire WP 3rd, Markman M: Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 2003;89(suppl 3):S3-S8.
7. Chen BJ: Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma 2001;42:253-265.
8. Qiu D, Kao PN: Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D 2003;4:1-18.
9. Lue Y, Sinha Hikim AP, Wang C, Leung A, Baravarian S, Reutrakul V, Sangsawan R, Chaichana S, Swerdloff RS: Triptolide: a potential male contraceptive. J Androl 1998;19:479-486.
10. Shamon LA, Pezzuto JM, Graves JM, Mehta RR, Wangcharoentrakul S, Sangsuwan R, Chaichana S, Tuchinda P, Cleason P, Reutrakul V: Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii. Cancer Lett 1997;112:113-117.
11. Lee KY, Chang W, Qiu D, Kao PN, Rosen GD: PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem 1999;274:13451-13455.
12. Jiang XH, Wong BC, Lin MC, Zhu GH, Kung HF, Jiang SH, Yang D, Lam SK: Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor kappaB activation in gastric cancer cells. Oncogene 2001;20:8009-8018.
13. Yang Y, Liu Z, Tolosa E, Yang J, Li L: Triptolide induces apoptotic death of T lymphocyte. Immunopharmacology 1998;40:139-149.
14. Chan EW, Cheng SC, Sin FW, Xie Y: Triptolide induced cytotoxic effects on human promyelocytic leukemia, T cell lymphoma and human hepatocellular carcinoma cell lines. Toxicol Lett 2001;122:81-87.
15. Zhang TM, Chen ZY, Lin C: Antineoplastic action of triptolide and its effect on the immunologic functions in mice (author's transl) (in Chinese). Zhongguo Yao Li Xue Bao 1981;2:128-131.
16. Lu LH, Lian YY, He GY, Lin SP, Huan SH, Chen ZZ, Dend HX, Zheng YL: Clinical study of triptolide treatment of acute leukemia. Clin Exp Investig Hematol 1992;3:1-3.
17. Kiviharju TM, Lecane PS, Sellers RG, Peehl DM: Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 2002;8:2666-2674.
18. Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF, Yang J, Underhill CB, Zhang L: Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003;2:65-72.
19. Lee KY, Park JS, Jee YK, Rosen GD: Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NFkappaB activation. Exp Mol Med 2002;34:462-468.
20. Chang WT, Kang JJ, Lee KY, Wei K, Anderson E, Gotmare S, Ross JA, Rosen GD: Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem 2001;276:2221-2227.
21. Fidler JM, Li K, Chung C, Wei K, Ross JA, Gao M, Rosen GD: PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther 2003;2:855-862.
22. Vasey PA: Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 2003;89(suppl 3):S23-S28.
23. Ferreira CG, Tolis C, Giaccone G: p53 and chemosensitivity. Ann Oncol 1999;10:1011-1021.
24. Blumenthal RD, Leone E, Goldenberg DM, Rodriguez M, Modrak D: An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression. Int J Cancer 2004;108:293-300.
25. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001;107:241-246.
26. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Saito M, Kawagoe J, Takahashi K, Yada-Hashimoto N, Sakata M, Motoyama T, Kurachi H, Tasaka K, Murata Y: Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 2004;279:23477-23485.
27. Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S, Ng JC, Kao PN: Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NFkappaB transcriptional activation. J Biol Chem 1999;274:13443-13450.
28. Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, Nicosia SV, Cheng JQ: AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 2005;10:975-987.
29. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
30. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV, Cheng JQ: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000;19:2324-2330.
31. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T, Murata Y: Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 2000;60:5988-5994.
32. Westfall SD, Skinner MK: Inhibition of phosphatidylinositol 3-kinase (PI3K) sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment. Mol Cancer Ther 2005;4:1764-1771.
33. Nilsson EE, Westfall SD, McDonald C, Ligon T, Sadler-Riggleman I, Skinner MK: An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics. Cancer Chemother Pharmacol 2002;49:93-100.
34. Altman DG: Practical Statistics for Medical Research, ed 1. New York, Chapman & Hall, 1991.
35. Raff M: Cell suicide for beginners. Nature 1998;396:119-122.
36. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 1997;326:1-16.
37. Schuijer M, Berns EM: TP53 and ovarian cancer. Hum Mutat 2003;21:285-291.
38. Zhao G, Vaszar LT, Qiu D, Shi L, Kao PN: Anti-inflammatory effects of triptolide in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2000;279:L958-L966.